Global H. Pylori (Helicobacter Pylori) Test Market Research Report: By Test Type (Non-Endoscopic, Endoscopic), By Technology (Immunoassays, Point-of-Care (POC), Molecular Diagnostics) and By End-User (Hospitals and Clinics, Diagnostics Laboratories, Others) – Forecast to 2027

Market Forecast

H. Pylori (Helicobacter Pylori) Test Market is expected to hold a value of USD 2,924.2 Million by 2025 at a CAGR of 5.2%.

Helicobacter pylori tests are used to detect an H. pylori infection in the stomach and upper part of the small intestine (duodenum). There has been a high burden of helicobacter pylori across the world. H. pylori infection is one of the world's most common an. In 2019, the prevalence of H. pylori infection reported a wide range from 18.9% in Switzerland up to 87.7% in Nigeria.

Market Influencer

In 2015, the worldwide prevalence of H. pylori was 4.4 billion individuals, and currently, it ranges between 85% and 95% in developing countries and between 30 and 50% (out of total population) in developed countries. Thus, the worldwide prevalence of H. pylori would influence the market growth during the study period. Global rising incidence of H. pylori infections accompanied by dyspepsia, availability of diagnostic tests, the presence of contaminated water or food, poor sanitation, high dense population, and poor personal hygiene are the factors expected to support the market growth over the assessment period.

Market Drivers

• Worldwide surging target patient population

• The rising burden of H. pylori and associated dyspepsia

• Growing awareness about H. pylori diagnosis among individuals: In October 2019, the Healthy Stomach Initiative (HSI) taken the initiative to raise awareness of and boost research about gastric cancer and associated H. pylori infection. About 90% of gastric cancer cases are related to H. pylori in the European Union (EU) every year. This is propelling the demand for the H. pylori diagnosis thereby nurturing the market growth.

• Improved cost-effectiveness of H. pylori diagnosis: Serology testing and stool antigen testing are more cost-effective than the currently most recommended C-urea breath test. Moreover, the decision analysis model indicates that the H. pylori test and treat strategy is the most cost-effective method for managing dyspepsia and currently costing USD 134/patient/year compared with USD 240 per patient per year for prompt endoscopy in the UK.

• Globally increasing geriatric population

Market Restraint

• The low number of diagnosis tests opted by patients

Segmentation

By Test Type

• Non-Endoscopic: This segment has been further categorized as stool/fecal antigen test (SAT), urea breath test (UBT), and serology/antibody/blood test. The non-endoscopic segment is expected to dominate the market during the forecast period as SAT and UBT are recommended for the diagnosis of H. pylori infection and the evaluation of the effectiveness of treatment.

• Endoscopic: This segment has been divided into culture, histology, rapid urease/Campylobacter-like organism (CLO) test, and polymerase chain reaction (PCR).

By Technology

• Immunoassays: The immunoassays segment spearheaded the market in 2018 due to the higher adoption of enzyme immunoassays for the detection of antibodies.

• Point-of-Care (POC): Non-invasive H. pylori diagnostic tests are available for point-of-care use in primary care and include IgG serology, monoclonal stool antigen, and C-urea breath test.

• Molecular Diagnostics: Molecular diagnostic methods such as polymerase chain reaction provides marginal improvements when done on biopsy material and can precisely identify H. pylori in areas outside the stomach where cultures usually fail.

By End-User

• Hospitals and Clinics: A gradual rise in the number of government and private hospitals in emerging nations such as China and India, along with an increase in the number of pylori tests performed in hospitals and clinics, are expected to support the dominance of this segment.

• Diagnostics Laboratories: Expected to register the fastest CAGR during the forecast period due to the rising number of healthcare facilities and medical laboratories around the globe.

• Others: This segment comprises ambulatory surgery centers, etc.

By Region

• Americas: The presence of diagnostic companies such as Thermo Fisher Scientific Inc., Bio-Rad Laboratories, Inc., Quest Diagnostics Incorporated, Cardinal Health, and Abbott Laboratories in the US facilitates early product (test kits, reagents/assays, etc.) launches of along with prompt product supply in the market, thereby supporting the dominance of Americas

• Europe: Europe is expected to be the second-largest market, following the Americas in terms of value during the forecast period. Resistance to antibiotics commonly used to treat Helicobacter pylori infection has increased manifold in the region in the past 20 years. This may reflect overconsumption of antibiotics and lack of support for programs aimed at curbing resistance in the near future.

• Asia-Pacific: Asia-Pacific is projected to represent lucrative market growth owing to the presence of target population base and poor sanitation conditions in the region coupled with the rising burden of the H. pylori infection

• Middle East & Africa: The market in this region will register the modest market growth. For instance, in 2018, the prevalence of H. pylori in Oman and Saudi Arabia was 49.1% and 65.9%, respectively. This prevalence is likely to contribute to regional market growth.

Key Players

• Thermo Fisher Scientific Inc. (US)


• Bio-Rad Laboratories, Inc. (US)


• Hoffmann-La Roche Ltd (Switzerland)


• Quest Diagnostics Incorporated (US)


• Meridian Bioscience (US)


• CorisBioconcept SPRL (Belgium)


• Cardinal Health (US)


• QIAGEN (Germany)


• Abbott Laboratories (US)


• Biohit Oyj (Finland)

Frequently Asked Questions (FAQ) :

---